Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR 0.0070
0.00 (0.00%)
Sep 2, 2026, 4:20 PM CET
Fidia Revenue
In the year 2025, Fidia had annual revenue of 29.49M EUR with 39.76% growth. Fidia had revenue of 15.96M in the half year ending December 31, 2025, a decrease of -11.83%.
Revenue (ttm)
28.68M
Revenue Growth
+6.09%
P/S Ratio
0.11
Revenue / Employee
209.33K
Employees
146
Market Cap
3.50M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.49M | 8.39M | 39.76% |
| Dec 31, 2024 | 21.10M | -9.05M | -30.02% |
| Dec 31, 2023 | 30.15M | 5.54M | 22.52% |
| Dec 31, 2022 | 24.61M | 573.00K | 2.38% |
| Dec 31, 2021 | 24.03M | 2.27M | 10.43% |
| Dec 31, 2020 | 21.76M | -26.24M | -54.66% |
| Dec 31, 2019 | 48.00M | -10.91M | -18.52% |
| Dec 31, 2018 | 58.92M | 10.96M | 22.84% |
| Dec 31, 2017 | 47.96M | -11.66M | -19.56% |
| Dec 31, 2016 | 59.62M | -3.71M | -5.86% |
| Dec 31, 2015 | 63.33M | 6.02M | 10.51% |
| Dec 31, 2014 | 57.31M | 11.53M | 25.18% |
| Dec 31, 2013 | 45.78M | -3.94M | -7.93% |
| Dec 31, 2012 | 49.72M | 4.20M | 9.21% |
| Dec 31, 2011 | 45.53M | -3.24M | -6.64% |
| Dec 31, 2007 | 48.76M | 6.64M | 15.76% |
| Dec 31, 2006 | 42.13M | 7.21M | 20.64% |
| Dec 31, 2005 | 34.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Interpump Group | 2.08B |
| Biesse | 650.82M |
| SIT S.p.A. | 316.17M |
| Tesmec | 273.24M |
| ILPRA | 86.81M |
| Marzocchi Pompe | 37.47M |
| OSAI Automation System | 34.56M |
| Valtecne | 31.33M |
Fidia News
- 2 hours ago - US medical groups urge people to get flu and Covid shots in counter to Trump guidance - The Guardian
- 3 hours ago - Johnson & Johnson Shares Jump Toward the Record High After FDA Approval; UBS Lifts Target to $320 - International Business Times (Australia)
- 3 hours ago - UTHR Looks 20.1% Overvalued on GF Value⢠as FDA Expands Tyvaso Label - GuruFocus
- 3 hours ago - Altria sues FDA over tobacco product review system - Reuters
- 3 hours ago - Scholar Rock (SRRK) Gains FDA Fast Track for Apitegromab Amid High Price-to-Sales Valuation - GuruFocus
- 4 hours ago - SciSparc Subsidiary Pursues FDA Orphan Drug Status For Tourette Syndrome Drug - Nasdaq
- 5 hours ago - UTHR Looks 20.1% Overvalued on GF Value⢠as FDA Review Progresses - GuruFocus
- 5 hours ago - Scholar Rock: FDA Grants Fast Track And Orphan Drug Designations To Apitegromab - Nasdaq